Please visit www.regenbiopharma.com/ and read associated DD
Bio-Matrix Scientific Group's Regen BioPharma Subsidiary Executes Option Agreement to
License Stem Cell Intellectual Property
SAN DIEGO, CA--(Marketwire - Jun 7, 2012) - Bio-Matrix Scientific Group, Inc. (OTCQB:
BMSN) (PINKSHEETS: BMSN) announced today that its wholly owned subsidiary Regen
BioPharma, Inc. has executed an exclusive option agreement which grants Regen BioPharma an
option to license Patent #6,821,513 which patents methods of stimulating blood production in
patients with deficient stem cells. The patent, as well as data licensed with the patent, covers
methods of stimulating the bone marrow to generate new blood cells. The patent and option
agreement are disclosed in the Company's most recent 8K filed with the US Securities and
Exchange Commission on June 6, 2012.
"The technology has broad applicability to help cancer patients recover faster following
chemotherapy, as well as for recipients of bone marrow and cord blood transplants. Currently,
new blood cell production is stimulated by expensive drugs such as Neupogen and Neulasta
which replicate the body's growth factors but can cause side effects and rely upon the diminished
recuperative powers of an immune compromised patient," stated J. Christopher Mizer, President
of Regen BioPharma.
David Koos, Chairman & CEO of Bio-Matrix Scientific Group, added, "We are excited to get
this therapy into the clinic. Based on peer-reviewed published animal data, it has the potential to
restore immune function faster and more effectively than the existing standard of care."
The licensed technology covers the use of a naturally-occurring cell type for stimulation of bone
marrow stem cells. By utilizing cells as opposed to drugs, Regen BioPharma believes it
possesses a substantial advantage to existing approaches in terms of safety and economics of
production. Currently the market for growth factors that stimulate blood making stem cells is
more than $4.84 billion per year (www.wikinvest.com/stock/Amgen).
About Bio-Matrix Scientific Group Inc. and Regen BioPharma, Inc.:
Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN) (PINKSHEETS: BMSN) is a biotechnology
company focused on the development of regenerative medicine therapies and tools. The
Company is focused on human therapies that address unmet medical needs. Specifically, Bio-
Matrix Scientific Group Inc. is looking to increase the quality of life through therapies involving
stem cell treatments. These treatments are focused in areas relating to cardiovascular,
hematology, oncology and other indications.
Through Its wholly owned subsidiary, Regen BioPharma, it is the Company's goal to develop
translational medicine platforms for the rapid commercialization of stem cell therapies. The
Company is looking to use these translational medicine platforms to advance intellectual
property licensed from entities, institutions and universities that show promise towards fulfilling
the Company's goal of increased quality of life.
Disclaimer
This news release may contain forward-looking statements. Forward-looking statements are
inherently subject to risks and uncertainties, some of which cannot be predicted or quantified.
Future events and actual results could differ materially from those set forth in, contemplated by,
or underlying the forward-looking statements. The risks and uncertainties to which forward looking
statements are subject include, but are not limited to, the effect of government
regulation, competition and other material risks.
Direct Copy from Source: www.regenbiopharma.com/pdf/regen-release-06-07-2012.pdf
$$$$SO LONG, SO STRONG...GO BMSN$$$$
